Literature DB >> 19639200

The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer.

Xiaokun Shen1, Lingzhi Hong, Huiming Sun, Minke Shi, Yong Song.   

Abstract

High-mobility group protein box 1 (HMGB1) released from dying tumor cells promotes tumor progression, on the other hand HMGB1 activates dendritic cells and triggers anti-neoplastic response of T-cells in chemotherapy and radiotherapy. HMGB1 expression is up-regulated in many kinds of tumors. To investigate HMGB1 expression in non-small cell lung cancer, 63 patients were enrolled and tumor tissues were collected with matched normal lung tissues. HMGB1 mRNA and protein levels were quantified with real-time PCR, Western blots and immunohistochemistry. The HMGB1 expression in tumor tissue was lower than in matched normal lung tissue at mRNA levels (Paired t-test, t<0.001) and the down-regulation in stage III-IV patients was also significantly greater than one in stage I-II (one-way ANOVA, p=0.005). At protein level, HMGB1 expression was also down-regulated. Low HMGB1 expression in non-small cell lung cancer may explain the poor therapeutical outcome during chemotherapy and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639200     DOI: 10.3892/or_00000468

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  25 in total

1.  Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma.

Authors:  Jintao Zhang; Kaijuan Wang; Jianzhong Zhang; Samuel S Liu; Liping Dai; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2011-05-03       Impact factor: 4.466

2.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

Review 3.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

4.  Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Authors:  Jiliang He; Peng Zhang; Qinghu Li; Dongsheng Zhou; Ping Liu
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

5.  HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer.

Authors:  Yirong Xu; Zhenwen Chen; Guangheng Zhang; Yanfeng Xi; Ruifang Sun; Fei Chai; Xiaogang Wang; Jianhong Guo; Lin Tian
Journal:  Tumour Biol       Date:  2015-06-18

Review 6.  High-mobility group box 1 and cancer.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Biochim Biophys Acta       Date:  2010 Jan-Feb

Review 7.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Authors:  T Yamazaki; D Hannani; V Poirier-Colame; S Ladoire; C Locher; A Sistigu; N Prada; S Adjemian; J P P Catani; M Freudenberg; C Galanos; F André; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-28       Impact factor: 15.828

10.  Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.

Authors:  Ming-Cheng Chang; Yu-Li Chen; Han-Wei Lin; Ying-Cheng Chiang; Chi-Fang Chang; Shu-Feng Hsieh; Chi-An Chen; Wei-Zen Sun; Wen-Fang Cheng
Journal:  Mol Ther       Date:  2017-11-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.